Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)

Table 3 Prevalence of dyslipidemia at baseline (BL) and follow-up (FU) by riskgroups and p-values for comparison of proportions.

	T2DM (n = 1238)		CHD (n = 520)		10-year CHD risk > 20% (n = 258)		Difference (T2DM vs CHD) P-value		Difference (T2DM vs 10-year CHD risk > 20%) P-value		Difference (CHD vs 10-year CHD risk >20%) P-value
	BL	FU	BL	FU	BL	FU	BL	FU	BL	FU	BL	FU
Elevated TC	95%	67%	90%	66%	93%	69%	< 0.001	0.691	0.39	0.381	0.098	0.289
Elevated LDL-C	92%	60%	92%	65%	95%	72%	0.834	0.048	0.221	< 0.0001	0.208	0.032
Elevated TGs	72%	59%	49%	39%	74%	53%	< 0.0001	< 0.0001	0.585	0.054	< 0.0001	< 0.0001
Low HDL-C	47%	42%	35%	27%	51%	36%	< 0.0001	< 0.0001	0.223	0.043	< 0.0001	0.017
Low HDL and/or elevated TG's	80%	69%	60%	50%	83%	66%	< 0.0001	< 0.0001	0.435	0.294	< 0.0001	< 0.0001
Elevated LDL-C and low HDL-C and/or elevated TG's	73%	41%	53%	32%	77%	48%	< 0.0001	< 0.0001	0.157	0.045	< 0.0001	< 0.0001
Elevated LDL-C and/or low HDL-C and/or elevated TG's	100%	88%	100%	83%	100%	90%	0.123	0.13	-	0.242	0.481	0.008

TC = total cholesterol, LDL-C = low-density lipoprotein, TG = triglycerides, HDL-C = high-density lipoprotein.

ISSN: 1471-2458